Further validation in larger cohorts and the development of standardized assays for Gal-9 detection in tumor tissue or liquid biopsies are necessary steps towards evaluating its potential integration into clinical decision-making algorithms or as a target for novel immunotherapies. This evidence concerns the gene LGALS9 and neoplasm.